Pharmacology News and Research

Latest Pharmacology News and Research

Austrian AGES approves Baxter's PREFLUCEL vaccine for seasonal influenza

Baxter International Inc. today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES). The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly. PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.

From Baxter International Inc. 30 Sep 2010

UNC scientists receive grant to develop targeted delivery system for pancreatic cancer

A team of UNC scientists has received a five-year $2,308,800 grant from the National Cancer Institute's Cancer Nanotechnology Platform Partnerships to address the critical need for early diagnosis of and more effective treatments for pancreatic cancer.

30 Sep 2010

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research. The NINDS grants will provide a five-year investment totaling more than $16 million for Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

29 Sep 2010

Researchers unveil mechanism of candida infections

More than half of all people are hosts to Candida albicans in their bodies. This species might be located on their skin or mucous membranes or in the intestines frequently without causing any symptoms. However, it can be dangerous to patients whose immunological system has been weakened such as after organ transplants or chemotherapy with cancer. Then, this fungus penetrates into deeper layers of tissue and uses the blood system to spread throughout the body. In Germany alone, several thousand people die from systemic candida infections every year.

29 Sep 2010

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Mayo Clinic, Arizona Cancer Center, and the Translational Genomics Research Institute (TGen).

29 Sep 2010

c-Met could be a potential personalized target for metastatic HCC

Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

MediciNova receives FDA approval to proceed with initial trial of ibudilast

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported FDA's approval to proceed with an initial trial of the company's neurological drug candidate, ibudilast (MN-166/AV411), as a potential new pharmacotherapy for methamphetamine addiction.

27 Sep 2010

PAREXEL Consulting releases two new white papers on biosimilar development

PAREXEL Consulting, a business unit of PAREXEL International and leading global life sciences consultancy serving the biopharmaceutical and medical device industries, today released two new white papers from leading biosimilar experts that provide key insights into emerging areas of biosimilar development.

From Parexel 24 Sep 2010

PharmacoEconomics releases special issue on CER

Wolters Kluwer Pharma Solutions, a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, announced today that the Adis journal PharmacoEconomics has released a special issue devoted entirely to comparative effectiveness research (CER).

23 Sep 2010

Resistance training program can help maintain metabolic health: Research

Although obesity is a major risk factor for disease, much of the threat may be associated with the metabolic (or cardiometabolic) syndrome, a cluster of risk factors related to diabetes and heart disease. Losing weight can improve health and reduce many of these risk factors. However, many people struggle to keep the weight off long-term.

23 Sep 2010

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

Evotec AG today announced that it has entered into a collaboration with Almirall S.A. to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

23 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

UC researcher receives NIDA’s Avant-Garde Award for cocaine addiction research

A University of Cincinnati (UC) researcher will receive $2.5 million over five years from the National Institute on Drug Abuse (NIDA) to support his work on a potential immunotherapy for cocaine addiction.

22 Sep 2010

Researchers explain how nerve cells transmit electrical signals

Billions of brain cells are communicating at any given moment. Like an organic supercomputer they keep everything going, from breathing to solving riddles, and "programming errors" can lead to serious conditions such as schizophrenia, Parkinson's disease and attention-deficit hyperactivity disorder.

22 Sep 2010

NIH awards UCSF $15.4 million to set up new National Center for Systems Biology

Cell biologists at UCSF have received $15.4 million from the National Institutes of Health to set up one of two new National Centers for Systems Biology, to study how cells respond to their environment - an emerging field of research that could revolutionize medicine by creating "smart cells" to deliver medications and other therapeutics more effectively.

22 Sep 2010

NIGMS director wins 2011 ASBMB Public Service Award

The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.

21 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010

Discovery could lead to new treatment methods for toxoplasmosis

The parasite responsible for toxoplasmosis requires a stress response system that helps it survive the move to infect new cells, Indiana University School of Medicine scientists have reported, a discovery that could lead to new treatments to control the disease.

21 Sep 2010

NIH awards grant to discover drug for alcoholism

With the ultimate goal to discover a drug that one day treats alcoholism, a University of Houston (UH) pharmacy professor is working on pinpointing the mechanisms in the brain that respond to alcohol.

21 Sep 2010